Categories AlphaGraphs, Earnings, Health Care
Earnings: Regeneron Pharmaceuticals (REGN) Q4 profit falls as revenues drop 31%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Friday reported a sharp fall in fourth-quarter revenues and adjusted earnings.
Total revenues plunged 31% year-over-year to $3.41 billion in the three months ended December 2022. Excluding REGEN-COV and Ronapreve, however, revenues increased by 14%.
The biotechnology firm’s fourth-quarter adjusted earnings nearly halved to $12.56 per share from $23.42 per share in the same period of 2021. Unadjusted profit was $1.20 billion or $10.50 per share, compared to $2.23 billion or $19.69 per share last year.
“In 2023, we remain committed to achieving the full potential of our diverse commercial- and clinical-stage portfolio, with a particular focus on aflibercept 8 mg, Dupixent in a variety of type 2 allergic diseases, and our promising oncology and hematology assets,” said the company’s CEO Leonard Schleifer.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Take-Two Interactive Software (TTWO) Earnings: 4Q24 Key Numbers
Take-Two Interactive Software, Inc. (NASDAQ: TTWO) reported net revenue of $1.40 billion for the fourth quarter of 2024, which was down 3% year-over-year. Net loss was $2.90 billion, or $17.02
Applied Materials (AMAT) Earnings: 2Q24 Key Numbers
Applied Materials, Inc. (NASDAQ: AMAT) reported revenue of $6.65 billion for the second quarter of 2024, which remained flat year-over-year. GAAP net income increased 9% to $1.72 billion and EPS
What to expect when Macy’s (M) reports its Q1 2024 earnings results
Shares of Macy’s, Inc. (NYSE: M) stayed green on Thursday. The stock has gained 23% over the past 12 months. The retailer is scheduled to report its first quarter 2024
